Q3 Revenue Up 46% to $1.06M as Margins Exceed 50%
INBS•Intelligent Bio Solutions posted fiscal Q3 revenue of $1.06 million, up 46% year-over-year, driven by a 59% increase in cartridge sales representing 66% of quarterly revenue and gross profit margin expanding to 50.5%. Nine-month revenue rose 39% to $3.07 million, with cash on hand of $6.86 million and cost-efficient marketing spending.
1. Q3 Financial Results
In the fiscal third quarter ended March 31, Intelligent Bio Solutions generated $1.06 million in revenue, a 46% increase year-over-year, led by $703,538 in cartridge sales (up 59% and representing 66% of the quarter). Gross profit margin expanded to 50.5% and cash and equivalents climbed to $6.86 million at quarter end.
2. Operational Milestones
The company advanced its FDA 510(k) regulatory program, completing penetration testing, a clinical cut-off study, and initiating cartridge validation targeting 70% faster results. A new manufacturing partnership enabled shipment of readers under optimized production, supporting improved unit economics.
3. Strategic Initiatives and Partnerships
Marketing investment of $1.77 million over nine months drove 39% revenue growth, while Q3 marketing spend fell 42% year-over-year as efficiency improved. The rollout with Bouygues UK and the grant of an eighth European patent bolster market expansion and IP protection ahead of U.S. market entry.
